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Abstract
Purpose of Review Here, we review recent literature indicat-
ing a role of innate lymphoid cells in human inflammatory
bowel disease with a focus on the plastic population of ILC3.
Recent Findings Many studies suggest an involvement of
ILC3 in human intestinal inflammation. ILC3 present the
most abundant ILC subtype in the human intestine at steady
state. In IBD, this composition is skewed towards ILCs show-
ing an ILC1 phenotype and cytokine profile. This change is
likely due to the microenvironment causing skewing of the
functionally plastic ILC subsets. Interactions between ILCs
and other cells are important to keep homeostasis and intesti-
nal barrier integrity.
Summary The knowledge about the involvement of ILCs in
IBD is rapidly increasing, and with the help of mouse models,
new pathways and functions of ILCs are continuously
unraveled. In the majority of human studies, a potential role
for ILCs in Crohn’s disease is found. However, less data is
available for a possible role in ulcerative colitis. Results from
mice are obtained from diverse model systems, and more re-
search in this field is needed to clarify and integrate the current
knowledge in order to improve treatment strategies for IBD
patients.
Keywords Innate lymphoid cells . ILC3 . Inflammatory
bowel disease . Intestinal homeostasis
Introduction
Inflammatory bowel disease (IBD) is an increasing medical
problem with a strongly impaired quality of life for the pa-
tients. Until today, the causes and molecular mechanism of the
disease are not clear and the available treatment regimens are
unsatisfying. A role for adaptive immune cells in IBD has
been established, and more recently, the innate immune sys-
tem has attracted attention in the context of IBD.Many studies
indicate a role for innate lymphoid cells (ILCs) in the patho-
genesis of IBD. In this review, we aim to summarize the latest
literature on this topic and to put the available studies into a
broader context, providing an interpretation of the meaning
for IBD disease pathogenesis.
Classification of Human Innate Lymphoid Cells
Innate lymphoid cells (ILCs) are a recently discovered group
of innate immune cells. They are detected in many organs
(blood, tonsils, thymus, liver, gut, lung, skin, uterus, and bone
marrow) [1] and are especially enriched in mucosal tissues of
the human body. ILCs are a relatively rare cell type, compris-
ing only about 0.1–13 % of CD45+ leukocytes depending on
the organ [2]. Over the last years, ILCs have been shown to
play crucial roles in the control of tissue homeostasis, as ef-
fector cells in the immune responses to infections and in in-
flammatory conditions [3].
ILCs develop from the common lymphoid progenitor
(CLP) under the influence of IL-2Rγc signaling and
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expression of the inhibitor of DNA-binding 2 (Id2) [4].
Whereas the ontogeny of ILCs in mice is becoming increas-
ingly understood [5], the exact developmental pathways of
ILCs in humans are still unclear. Commonly, ILCs are defined
by a lymphoid morphology, by the absence of markers for
myeloid and dendritic cells (DCs) and, in contrast to T or B
cells, by the lack of recombination activating gene (RAG)-
dependent rearranged antigen receptors [6].
Up until now, the family of ILCs has been divided into three
subgroups, group 1, 2, and 3 ILCs (ILC1, ILC2, and ILC3),
based on their transcription factor and cytokine production
profile (Fig. 1). This classification is reflecting the classifica-
tion of T helper cells in the adaptive arm of the immune sys-
tem. Thus, ILCs are considered the innate counterparts of Th1,
Th2, and Th17/22 cells. In contrast to T helper cells, ILCs
respond rapidly to cytokine stimulation in the absence of spe-
cific antigens but once activated, they display similar effector
functions as the respective groups of T helper cells [7].
Human ILC1 is a heterogeneous group comprised of NK
cells, intraepithelial CD127− ILC1 [8•], and CD127+ ILC1
[9••]. The former two subsets may be described as the innate
counterparts of CD8+ Tcells as they exert cytotoxicity and are
hence not referred to as Bhelper^ types of ILC1. In contrast,
CD127+ ILC1 lack effector molecules associated with cyto-
toxicity, such as perforin and granzyme B, and are therefore
more similar to CD4+ helper T cells. Hence, they are consid-
ered to be the innate equivalents of Th1 cells. Mouse studies
have shown that intraepithelial ILC1 and conventional NK
cells are different lineages, and that they are developmentally
separated from helper ILCs [10••]. All ILC1 express the tran-
scription factor T-bet whereas NK cells and intraepithelial
ILC1 additionally express eomesodermin (Eomes).
Commonly, ILC1 produce the signature cytokine IFN-γ fol-
lowing stimulation with IL-12 and IL-18 [11]. Together, the
physiological role for ILC1 seems to be immune responses to
intracellular pathogens and tumors.
ILC2 were first described in mice [12–14] and later in
humans [15, 16] as cells dependent on the transcription factors
Gata-binding protein 3 (GATA3) and retinoic acid receptor
(RAR)-related orphan receptor α (RORα) for their develop-
ment [17–19]. ILC2 display a type-2 cytokine profile. In re-
sponse to stimulation with IL-33, IL-25, or TSLP [13, 19, 20],
they produce mainly IL-13 and IL-5, but also IL-4, IL-6, IL-8,
IL-9, GM-CSF and in mice, amphiregulin [14, 15, 19, 21]. In
Fig. 1 Classification of human
ILCs. Human ILCs are divided
into three broad subgroups called
group 1, group 2, and group 3
ILCs based on the expression of
transcription factors and cytokine
production
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addition, they express the prostaglandin D2 (PGD2) receptor
CRTH2 [16] and respond to PGD2 stimulation with the pro-
duction of type 2 cytokines [22]. In mice, ILC2 were shown to
play a role in helminth expulsion [13].
ILC3 are defined by the expression of the RAR-related
orphan receptor-γt (RORγt) [23] and surface expression of
CD117 (c-kit) [24]. They respond to stimulation with IL-23
and IL-1β with production of the Th17/Th22 cytokines IL-
17A, IL-17F, and IL-22, either alone or in combinations [23,
24]. The group of human ILC3 includes fetal lymphoid tissue
inducer (LTi) cells [25] and postnatal ILC3, which can be
further divided according to the expression of the activating
NK cell receptor NKp44 [26]. LTi cells are critically involved
in the development of lymphoid organs during embryogenesis
through secretion of lymphotoxin-β and TNF-α. In addition,
LTi cells can express IL-17A and IL-22 [25]. Postnatally,
NKp44+ ILC3 are producing IL-22 but little IL-17 whereas
NKp44− cells produce IL-17 but limited amounts of IL-22
[26]. ILC3 are generally involved in the immune response to
extracellular pathogens [27].
All helper ILC subsets, i.e., with the exception of NK cells
and intraepithelial ILC1, are phenotypically defined by ex-
pression of the surface proteins CD161 and CD127 (IL-
7Rα) and dependence on IL-7 for their development [6].
Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) includes Crohn’s disease
(CD) and ulcerative colitis (UC). IBD is a chronic inflamma-
tion of the gastrointestinal tract, commonly attributed to a
dysregulated immune response against the intestinal bacteria
in genetically susceptible individuals. In addition, environ-
mental factors have been implicated in the onset of disease,
since the disease emerges in developing nations with western-
ized lifestyle and industrialization. Some of these factors
influencing the risk of IBD development either positively or
negatively are smoking, appendectomy, diet, medications, and
pollutants [28].
IBD severely reduces the quality of life for patients, with
the most common symptoms being diarrhea, abdominal pain,
rectal bleeding, weight loss, and fatigue. IBD patients are at
increased risk of developing other chronic autoimmune disor-
ders like psoriasis, ankylosing spondylitis, or primary scleros-
ing cholangitis. About 25 % of patients develop other extra-
intestinal manifestations of IBD like arthritis, uveitis, or skin
lesions [1, 29].
Up to now, the exact causes of IBD are not clear and there
is no curative treatment available. Most conventional drug
therapies, such as anti-inflammatory drugs, corticosteroids,
or immuno-suppressants [30], aim at symptomatic treatment.
Relatively recently, a group of new biological treatment
specimen, including anti-TNFα antibodies, has dramatically
improved the treatment options for IBD patients [31].
There are several differences observed in the type of in-
flammation present in UC or CD patients. Ulcerative colitis
usually affects the distal colon with continuous inflammation,
which is restricted to the mucosa. In contrast, Crohn’s disease
can affect the entire gastrointestinal tract and shows a discon-
tinuous and transmural inflammation [29]. In terms of the
immune mechanisms involved, UC is thought to be driven
by a type-2 response including increased levels of IL-13 and
IL-5 in the intestine and high expression of the type-2 driving
cytokine IL-33 and its receptor ST2 [32–34]. CD, on the other
hand, is considered a type-1 driven inflammation, character-
ized by increased numbers of Th1 cells and high IFN-γ levels
in response to IL-12 [32, 33, 35].
The microbiota plays a crucial role in disease pathogenesis.
IBD patients present with dysbiosis, changes in microbiota,
including a reduced diversity of Firmicutes and Bacteroidetes
[36]. A recent study on treatment-naïve pediatric CD samples
investigated the microbiotic changes in more detail and sug-
gested sampling of themucosal microbiota as a diagnostic tool
for IBD [37]. In patients suffering from IBD, the intestinal
epithelium shows an increased permeability, the Bleaky-gut
phenomenon^, which permits enhanced immune responses
against the commensal microbiota [29].
Until today, it is in large parts still unclear which of the
observed symptoms and immunological changes in IBD are
cause or consequence of the disease and more research in this
field is urgently needed.
ILC in Gut Homeostasis and Inflammatory Bowel
Disease
ILC3 in Gut Homeostasis
In the healthy human intestine, all currently known ILC pop-
ulations are present with ILC3 constituting the majority of
ILCs in the lamina propria of the ileum [9••] whereas pub-
lished data on the distribution of the ILC subsets in the healthy
human colon is missing.
ILC3 are shown to be crucially involved in intestinal ho-
meostasis (Fig. 2). Generally, ILC3 are known as producers of
IL-22 and/or IL-17 in response to IL-23 and IL-1β. IL-22 acts
on non-hematopoietic cells, such as epithelial cells, and
through its heterodimeric receptor, consisting of IL-22R1 plus
IL-10R2, and STAT-3 signaling induces mucosal wound
healing responses and epithelial cell proliferation [38, 39]. In
mice, it was further shown to mediate protection against in-
testinal pathogenic bacteria by inducing the production of a
variety of antimicrobial peptides, such as RegIIIβ, RegIIIγ,
S100A8, and S100A9, element-sequestering proteins, and
mucins [40].
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A second mechanism directly influencing the intestinal mi-
crobiotawas recently described inmice. ILC3 are involved in the
induction of Fut2 in intestinal epithelial cells, an enzyme which
mediates epithelial cell fucosylation [41]. This induction required
commensal-dependent IL-22 and commensal-independent
lymphotoxin (LT) production. Epithelial fucose is catabolized
by commensal bacteria and in this way supports homeostasis
of the microbiota and protection from pathogenic bacteria.
Another beneficial effector function of ILC3-derived IL-22
was observed in a mouse model of graft-versus-host disease
(GVHD) and tissue damage, where IL-22 acts on intestinal
stem cells to preserve the epithelial barrier integrity [42••,
43]. IL-22 production by ILC3 is enhanced through activation
of the transcription factor aryl hydrocarbon receptor (AHR).
AHR is a ligand-activated transcription factor with many li-
gands, such as tryptophan metabolites, occurring in the diet
and environment [44].
Another ILC3-derived cytokine, IL-17, is known to induce
the release of chemokines and other chemoattractants from
epithelial and endothelial cells, which enhance the inflamma-
tion response through recruitment of pro-inflammatory neu-
trophils [45]. However, protective effects of IL-17, for exam-
ple, in IBD, are also reported. One of the main inducers of IL-
17, IL-23, can be targeted by ustekinumab (anti-IL-12p40) for
successful IBD treatment [46]. However, targeting IL-17 itself
through secukinumab actually exacerbates IBD [47•]. This
dichotomy was recently explained by the observation that
IL-17 promotes epithelial barrier function in the absence of
IL-23 [48, 49•]. Hence, IL-23 independent IL-17 production is
protective, whereas IL-23 dependent IL-17 production might
be deleterious, as suggested by the numerous mouse studies
discussed in the next section.
How ILC3 are integrated into a complex network of intes-













































Fig. 2 ILC3 functions in gut homeostasis. ILC3 are stimulated by IL-23,
IL-1β, and TL1A, derived from MNPs and DCs to produce their
signature cytokines IL-22 and IL-17 as well as GM-CSF. IL-22
promotes epithelial barrier integrity and proliferation, induces
antimicrobial peptide and mucin production and, together with
lymphotoxin, enhances epithelial fucosylation. IL-22 production from
ILC3 can be also stimulated with epithelial cell-derived PGE2 whereas
dietary AHR ligands help maintain ILC3 in the intestine. IL-17 induces
the recruitment of neutrophils and also supports epithelial barrier
protection. GM-CSF has been shown to be important in the induction
of oral tolerance acting via DCs/MNPs. ILC3 were shown to inhibit
commensal-specific T cells via the MHCII receptor together with a
withdrawal of IL-2. Epithelial cell-derived IL-25 acts via MNPs/DCs to
inhibit ILC3 functions. IL-23, IL-1β, and RA can induce plasticity of
ILC1 and ex-ILC3 towards an ILC3 phenotype, whereas IL-12 can
reverse this effect under inflammatory conditions
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function, and therapeutic potential has only started to be
unraveled. A major source of the ILC3-stimulating factors
IL-23 or IL-1β in the human gut is CX3CR1
+ mononuclear
phagocytes (MNPs) or CD14− dendritic cells [50••, 51].
Mononuclear phagocytes play an important role in the main-
tenance of gut homeostasis. They can directly sense commen-
sal bacteria and subsequently stimulate ILC3 via IL-1β, IL-
23, and TL1A to produce effector cytokines IL-22 and GM-
CSF [51]. In a feedback loop, GM-CSF is a crucial regulator
of mononuclear phagocytes, which induce intestinal Treg cells
[52]. In this way, the crosstalk between mononuclear phago-
cytes and ILC3 is important in the induction of tolerance to-
wards commensals and dietary antigens. In mice, it was
shown that ILC3 responses are indirectly down-regulated via
IL-25, which is secreted by microbiota-stimulated epithelial
cells and likely acts via DCs, which in turn limits ILC3 acti-
vation through a so far unknown mechanism [53].
In addition to being regulated by immune cell subsets
such as DCs, ILC3 has the capacity to regulate the activity
of other immune cells via direct cell-cell interactions with
important implications for gut homeostasis. ILC3 were
shown to regulate adaptive T cell responses through the
expression of MHCII molecules. So far, most data are
based on mouse studies and the expression pattern of
MHCII molecules significantly differs between mouse and
human. However, it seems likely that ILC–T cell interac-
tions are also taking place in the human setting, since
MHCII (HLA-DR) expression was detected on human in-
testinal ILC3 [54••] and defines a transcriptionally and func-
tionally distinct ILC3 subset in the human tonsil [55•]. In
the mouse, ILC3 limited commensal bacteria-specific T cell
responses through MHCII-dependent interactions with
CD4+ T cells and this effect was independent of ILC3 ef-
fector cytokines. Later, it was shown that this intestinal T
cell selection is achieved by antigen presentation together
with IL-2 cytokine withdrawal mediated by MHCII+ ILC3
leading to programmed cell death of activated microbiota-
reactive T cells [56•]. Furthermore, ILC3 were able to pro-
cess and present antigen but lacked expression of the clas-
sical co-stimulatory molecules (CD40, CD80, CD86)
[54••]. In contrast, it was shown that ILC3 isolated from
mouse spleen express co-stimulatory molecules and induce
T cell responses and proliferation [57]. These controversial
observations might depend on the different microenviron-
ments in different anatomical locations, which favor vari-
able surface protein expression and diverse effector func-
tions of ILC3. Nevertheless, the capacity of ILC3 to regu-
late T cell activity partly explains their dramatic impor-
tance, at least in certain mouse models, despite their rela-
tive rareness.
In summary, ILC3 deploy an array of cytokine-dependent
and cell surface receptor-mediated mechanisms to exert ho-
meostatic control of intestinal immunity.
ILC3 in Inflammatory Bowel Disease
Naturally, since a number of mouse models that mimic gut
inflammation are available, a large amount of data indicating
a role for ILCs in IBD is obtained from mouse studies.
Nevertheless, many reports also indicate a role of ILCs in
the promotion of IBD in humans (Fig. 3). However, the het-
erogeneity and plasticity within the group of ILC3, the differ-
ent gating strategies used to identify ILC3, as well as the
diversity of mouse models employed contribute to some con-
fusion regarding the role for ILC3 in human gut inflammation.
Many genes related to ILC3 biology were identified in
genome-wide association studies (GWAS) as risk loci for
IBD. One key GWAS identified 163 risk loci for IBD, con-
taining genes involved in autophagy, several genes of the IL-
23/IL-17 pathway, mucins and NOD2, a gene important for
intracellular pathogen sensing [58]. Since human ILCs ex-
press a large number of these GWAS genes [55•], it is possible
that some IBD risk genes partly mediate their penetrance by
modifying ILC functions.
Indeed, a number of studies reported changes in the ILC
composition and function within the lamina propria of IBD
patients connected to those risk genes. These findings in
humans are supported by data from different mouse models
of intestinal inflammation. Two studies identified a decrease
of IL-22 producing ILC3 in the intestine of Crohn’s patients
[9••, 59]. The protective effect of ILC3-derived IL-22 in gut
inflammation was demonstrated in several mouse models. IL-
23-induced IL-22 was shown to attenuate colon inflammation
induced by dextran sodium sulfate (DSS) or Citrobacter
rodentium infection [60] and lack of IL-22 producing ILCs
increased susceptibility to C. rodentium [27, 61].
Furthermore, in the TCRα KO mouse model, representing a
model of UC, IL-22 gene delivery improved colitis through
mucin induction and goblet cell restitution [62]. However, in
contrast to these protective and regenerative effects of ILC-22,
Longman et al. found that colonic ILC3 from UC as well as
CD patients showed an increased IL-22 production capacity
[51] and a study using the anti-CD40 model of innate colitis
found a pathogenic role for IL-22 [63]. Hence, ILC3-derived
IL-22 has a complicated role in the intestine and cannot be
easily designated as protective.
Takayama et al. and Bernink et al. showed a decrease of IL-
22 producing NKp44+ ILC3 in the lamina propria of CD pa-
tients [9••, 59] but not UC patients [59]. One of the groups
showed that the decrease of NKp44+ ILC3 was accompanied
by a reciprocal increase of an IL-23 responsive IFN-γ-
producing cell population which showed an NK cell pheno-
type (CD3− CD56+ NKp44−NKp46+ CD127− RORgt−) [59].
Bernink et al., on the other hand, identified a population of
CD127+ ILC1 in humans that was found to be accumulated in
the lamina propria of CD patients at the expense of NKp44+
ILC3. These cells produced IFN-γ under stimulation with IL-
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12 and were unresponsive to IL-23 or IL-1β [9••]. Another
ILC1 subset, called intraepithelial ILC1, which resides in the
intestinal epithelium and produces large amounts of IFN-γ
upon IL-12 stimulation, was also amplified in the small intes-
tine of CD patients [8•]. These intraepithelial ILC1 were char-
acterized by expression of CD103, NKp44, granzymes, and
perforin and they expressed the transcription factors Tbet and
Eomes [8•]. Hence, several studies point to an accumulation
of, and a pathogenic role for, IFN-γ producing ILCs in human
gut inflammation, as shown in mice [64]. Indeed, IFN-γ is
known to promote gut inflammation by reducing tight junc-
tion integrity, enhancing leukocyte recruitment, and stimulat-
ing phagocytes [65].
Not only an increase of IFN-γ in the intestine of IBD pa-
tients was observed but also a pro-inflammatory role for IL-17
was suggested. An increased frequency of IL-23 responsive
IL-17- and IFN-γ-producing CD56− ILC3 in the intestine of
CD patients, but not in UC patients, was detected [66], and a
similar subset was found at elevated numbers in a mouse
model of Helicobacter hepaticus-induced colitis [64]. In ad-
dition, a mouse model of UC in Rag2−/− and Tbet−/− mice
(TRUC mice) suggested a central role for IL-23-induced IL-
17 in chronic intestinal inflammation [67]. However, as men-
tioned above, IL-23 and IL-17 seem to have opposed, yet
linked, roles where anti-IL-23 treatment improves both IBD
and experimental colitis [46, 47•, 49•, 68], whereas anti-IL-17
treatment worsens IBD [47•].
The skewed frequencies of ILCs in the intestine of IBD
patients could either be explained by specific recruitment of
cells to the intestine or by plasticity between the different ILC
subsets, induced by the inflammatory response. Indeed, a high
degree of plasticity among ILC subsets started to be recently
unraveled. Human ILC3 were shown to differentiate into
IFN-γ-producing ILC1 under IL-12 stimulation. IL-12 in-
duced down-regulation of RORγt, up-regulation of Tbet and
the cells lost the ability to produce IL-22. These ILC1-like
cells are termed Bex-ILC3^ [9••]. A similar conversion of
RORγt+ ILC3 to IFN-γ-producing RORγt− ILCs under IL-
12 stimulation was reported in mice [69]. Recently, IL-12 was
also shown to play a role in ILC2 plasticity. An increased
frequency of ILC2 in intestinal samples of Crohn’s patients


































Fig. 3 Changes of ILC frequencies and functions in intestinal
inflammation. In the inflamed intestine of Crohn’s patients, several
changes in the distribution of ILC frequencies have been observed.
Homeostatic NKp44+ ILC3 are decreased whereas the frequencies of
the IFN-γ-producing subsets of intraepithelial ILC1 and CD127+ ILC1
are increased. The IL-12 induced plasticity of NKp44+ ILC3 to ex-ILC3,
resembling ILC1 is likely contributing to this increased frequency.
Somewhat contradictory, NKp44+ ILC3 from the colon of UC and CD
patients were shown to have a higher capacity for IL-22 production. An
IL-17- and IFN-γ-producing CD56− subset of ILC3 was found to be
increased in the intestine of Crohn’s patients. In addition, the MHCII
expression on intestinal ILC3 from pediatric Crohn’s patients was shown
to be reduced and this correlated with an increased number of Th17 cells
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and IFN-γ [70•]. In vitro ILC2 could be induced to express
IFN-γ and Tbet under the influence of IL-12. If this mecha-
nism could play a role in the pathogenesis of UC is to date
unclear, and other reports studying the involvement of ILC2
in human IBD are eagerly anticipated. IL-12 is a pro-
inflammatory cytokine produced mainly by antigen present-
ing cells in response to bacterial products [71] and is present at
high levels in the inflamed gut mucosa. Clinical trials with a
monoclonal antibody against the shared p40 subunit of IL-12
and IL-23 could induce remission in Crohn’s disease [72], but
it is still unclear through which molecular mechanism im-
provement is achieved.
The conversion of ILC3 into ILC1 was recently shown to
be reversible. CD127+ ILC1 could differentiate into RORγt+
ILC3 under stimulation with IL-2, IL-23, and IL-1β, and this
was further enhanced by retinoic acid (RA) [50••]. This re-
versible plasticity is an elegant mechanism through which
ILCs can be instructed to adapt to the current needs in a certain
microenvironment without the recruitment of cells from the
circulation.
Not only a skewed profile of ILC3 effector cytokines but
also altered interactions of ILC3 within the intestinal immune
cell network is suggested to play a role in intestinal inflamma-
tion. ILC3 and T cell interaction seems to have a crucial func-
tion in keeping gut homeostasis. Mice with a deletion of
MHCII in the ILC3 developed spontaneous intestinal inflam-
mation in the presence of commensal bacteria with increased
frequencies of pro-inflammatory (IFN-γ +, IL17A+, TNFα+)
CD4+ T cells in the colon [54••]. In addition, it was found that
MHCII expression on colonic ILC3 from pediatric IBD pa-
tients is reduced together with an increased frequency of Th17
cells in the colon [56•], which suggests a protective regulatory
effect of MHCII expressing ILC3 in IBD.
As described above, the interaction of mononuclear phago-
cytes and ILC3 is important in the induction of intestinal tol-
erance towards commensals and dietary antigens. In the con-
text of IBD, some studies indicate that this crosstalk could be
disturbed in CD patients [52, 73, 74].
Furthermore, ILC3-derived IL-22 was shown to prevent
the dissemination of lymphoid-resident bacteria, specifical-
ly Alcaligenes, in mice [75]. Crohn’s disease is associated
with specific immune responses against Alcaligenes, which
suggests a dysregulation of this mechanism in human IBD
[75].
It is known that patients with inflammatory bowel disease
have an increased risk of developing colorectal cancer. As
described above, the IL-23 pathway is involved in intestinal
inflammation in several mouse models and IL-22 has a pro-
tective effect in some models of intestinal inflammation. On
the other hand, in the development of cancer, IL-22 can have a
pro-tumorigenic effect. One study reported ILC3- and IL-22-
dependent progression of colitis-associated colorectal cancer
in a mouse model [76•], which indicates the possibility of an
involvement of ILC3 in human colorectal cancer. These op-
posing protective and pathogenic effects of IL-22 indicate that
a tight regulation of this cytokine is necessary to maintain
homeostasis. An important regulator of IL-22 is the DC-
derived IL-22 binding protein (IL-22BP). Mice lacking IL-
22BP showed increased incidence of tumors in an IBD-
associated colorectal cancer model [77].
Conclusions
Important advances in our knowledge about immunological
mechanisms in intestinal inflammation have been made,
even if the initial trigger for the development of IBD is still
unidentified. It is becoming increasingly clear though, that
dysregulated ILCs are involved in the pathogenesis of IBD,
especially through the usage of mouse models of intestinal
inflammation. Different subsets of ILCs are expanded in the
disease states compared to homeostasis, and more and more
interactions of ILCs with other immune cells are being dis-
covered. However, many questions concerning which of the
observed alterations in ILC composition and function are
causes or consequences of the inflammation are still
unanswered.
Most research on humans investigating the role of ILCs in
IBD focused so far on Crohn’s disease, and not much data is
available for ulcerative colitis. Since UC is thought of as a
type 2 mediated inflammation, an interesting question is if
any changes in the ILC2 compartment and their function can
be observed in the disease state.
Integrating and expanding the knowledge obtained from
mouse models and confirming which role ILCs play in human
IBD will lead to a better understanding of intestinal immune
networks and will hopefully pave the way for better and final-
ly curative treatment of IBD.
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